INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3096% above fair value
$119.80−2.06 (-1.69%)
Close on Nov 18, 2026Market cap $26.28BP/E –Yield –
Insmed net income
Net income is the profit left for shareholders after every expense, interest and tax.
Insmed's net income for the twelve months ending Sep 30, 2026 was -$605.61M. For fiscal 2025 it was -$1.28B. The highest annual figure on record is $118.35M in fiscal 2009.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.28B | – |
| FY2024 | Dec 31, 2024 | -$913.77M | – |
| FY2023 | Dec 31, 2023 | -$749.57M | – |
| FY2022 | Dec 31, 2022 | -$481.53M | – |
| FY2021 | Dec 31, 2021 | -$434.65M | – |
| FY2020 | Dec 31, 2020 | -$294.09M | – |
| FY2019 | Dec 31, 2019 | -$254.34M | – |
| FY2018 | Dec 31, 2018 | -$324.28M | – |
| FY2017 | Dec 31, 2017 | -$192.65M | – |
| FY2016 | Dec 31, 2016 | -$176.27M | – |
| FY2015 | Dec 31, 2015 | -$118.18M | – |
| FY2014 | Dec 31, 2014 | -$79.16M | – |
| FY2013 | Dec 31, 2013 | -$56.07M | – |
| FY2012 | Dec 31, 2012 | -$41.37M | – |
| FY2011 | Dec 31, 2011 | -$59.66M | – |
| FY2010 | Dec 31, 2010 | -$6.43M | -105.4% |
| FY2009 | Dec 31, 2009 | $118.35M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$100.32M | – |
| Q2 FY2026 | Jun 30, 2026 | -$13.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$163.56M | – |
| Q4 FY2025 | Dec 31, 2025 | -$328.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$370.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$321.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$256.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$235.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$220.52M | – |
| Q2 FY2024 | Jun 30, 2024 | -$300.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$157.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$186.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$158.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$244.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$159.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$160.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$131.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$95.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$94.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$112.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$112.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$117.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$91.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -$102.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$63.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$61.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$66.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$52.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$60.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$66.51M | – |
| Q1 FY2019 | Mar 31, 2019 | -$74.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$91.57M | – |
| Q3 FY2018 | Sep 30, 2018 | -$87.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$76.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -$68.52M | – |
| Q4 FY2017 | Dec 31, 2017 | -$65.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$45.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$44.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$37.41M | – |
| Q4 FY2016 | Dec 31, 2016 | -$68.40M | – |
See a number that looks wrong?